{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:13:21Z","timestamp":1787505201671,"version":"build-2736575974"},"reference-count":142,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Gastroesophageal cancer (GEC) represents a global health burden, with rising incidence and high mortality. Despite advancements in early detection and systemic therapies, outcomes remain poor, especially in advanced stages. Management requires a multidisciplinary, multimodal approach that integrates surgery, chemotherapy, radiotherapy, targeted agents, and immunotherapy, tailored by tumor histology, location, and molecular profile. For localized disease, perioperative chemotherapy or chemoradiotherapy is standard, with adjuvant immunotherapy now emerging in selected high-risk cases. In metastatic or unresectable settings, systemic therapy forms the backbone of treatment, with biomarker-driven regimens targeting HER2, PD-L1, MSI-H\/dMMR, and CLDN18.2, offering improved outcomes. Novel agents and combinations, including bispecific antibodies, FGFR2 inhibitors, and immunotherapy-based strategies, are actively being explored in clinical trials. This review provides a comprehensive overview of the evolving therapeutic landscape of GEC. It emphasizes the growing role of precision medicine and the integration of emerging clinical data into practice.<\/jats:p>","DOI":"10.3390\/ijms262311424","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T11:43:22Z","timestamp":1764157402000},"page":"11424","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Therapeutic Frontiers in Gastroesophageal Cancer: Contemporary Concepts in Management and Therapy"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3895-9474","authenticated-orcid":false,"given":"Supriya","family":"Peshin","sequence":"first","affiliation":[{"name":"Norton Community Hospital, Norton, VA 24273, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9062-9761","authenticated-orcid":false,"given":"Ehab","family":"Takrori","sequence":"additional","affiliation":[{"name":"College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3955-9720","authenticated-orcid":false,"given":"Naga Anvesh","family":"Kodali","sequence":"additional","affiliation":[{"name":"HCA Florida Ocala Hospital, University of Central Florida, Ocala, FL 34471, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9634-613X","authenticated-orcid":false,"given":"Faizan","family":"Bashir","sequence":"additional","affiliation":[{"name":"School of Medicine, Shiraz University of Medical Sciences, Shiraz 71348-45794, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1500-9281","authenticated-orcid":false,"given":"Michael","family":"Gibson","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center, Nashville, TN 37232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakshi","family":"Singal","sequence":"additional","affiliation":[{"name":"Department of Hematology & Oncology, East Tennessee State University, Johnson City, TN 37614, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Lerut, T. (2001). Carcinoma of the Esophagus and Gastro-Esophageal Junction. Surgical Treatment: Evidence-Based and Problem-Oriented, Zuckschwerdt.","DOI":"10.1016\/S0960-7404(01)00027-5"},{"key":"ref_2","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0140-6736(22)01438-6","article-title":"The global burden of cancer attributable to risk factors 2010\u201319: A systematic analysis for the Global Burden of Disease Study 2019","volume":"400","author":"Tran","year":"2022","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Li, J.J., Rogers, J.E., Yamashita, K., Waters, R.E., Blum Murphy, M., and Ajani, J.A. (2023). Therapeutic Advances in the Treatment of Gastroesophageal Cancers. Biomolecules, 13.","DOI":"10.3390\/biom13050796"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.cell.2024.02.041","article-title":"Cancer Biomarkers-Emerging Trends and Clinical Implications for Personalized Treatment","volume":"187","author":"Passaro","year":"2024","journal-title":"Cell"},{"key":"ref_6","unstructured":"Wang, Y., Mukkamalla, S.K.R., Singh, R., and Lyons, S. (2025). Esophageal Cancer. StatPearls, StatPearls Publishing."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Korpan, M., Puhr, H.C., Berger, J.M., Friedrich, A., Prager, G.W., Preusser, M., and Ilhan-Mutlu, A. (2025). Current Landscape of Molecular Biomarkers in Gastroesophageal Tumors and Potential Strategies for Co-Expression Patterns. Cancers, 17.","DOI":"10.3390\/cancers17030340"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Sato, Y., Okamoto, K., Kawano, Y., Kasai, A., Kawaguchi, T., Sagawa, T., Sogabe, M., Miyamoto, H., and Takayama, T. (2023). Novel Biomarkers of Gastric Cancer: Current Research and Future Perspectives. J. Clin. Med., 12.","DOI":"10.3390\/jcm12144646"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"200857","DOI":"10.1016\/j.omton.2024.200857","article-title":"Unveiling Promising Targets in Gastric Cancer Therapy: A Comprehensive Review","volume":"32","author":"Li","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6884","DOI":"10.1245\/s10434-025-17386-7","article-title":"The Evolving Role of Immunotherapy for Gastroesophageal Malignancies","volume":"32","author":"Emiloju","year":"2025","journal-title":"Ann. Surg. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e431060","DOI":"10.1200\/EDBK_431060","article-title":"State-of-the-Art Advancements in Gastroesophageal Cancer Treatment: Harnessing Biomarkers for Precision Care","volume":"44","author":"Balmaceda","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Waddingham, W., Graham, D.G., and Banks, M.R. (2024). Latest Advances in Endoscopic Detection of Oesophageal and Gastric Neoplasia. Diagnostics, 14.","DOI":"10.3390\/diagnostics14030301"},{"key":"ref_13","first-page":"14","article-title":"Endoscopic Ultrasound Staging of Esophageal Cancer","volume":"16","author":"Thakkar","year":"2020","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4253\/wjge.v14.i4.205","article-title":"Role of Endoscopic Ultrasound in Esophageal Cancer","volume":"14","author":"Radlinski","year":"2022","journal-title":"World J. Gastrointest. Endosc."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00261-007-9241-1","article-title":"Role of PET\/PET CT in the Staging and Restaging of Thoracic Oesophageal Cancer and Gastro-Oesophageal Cancer: A Literature Review","volume":"33","author":"Wong","year":"2008","journal-title":"Abdom. Imaging"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1007\/s00261-020-02447-0","article-title":"Clinical Impact of FDG PET\/CT in Alimentary Tract Malignancies: An Updated Review","volume":"45","author":"Akin","year":"2020","journal-title":"Abdom. Radiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/ags3.12283","article-title":"Role of Staging Laparoscopy for Gastric Cancer Patients","volume":"3","author":"Fukagawa","year":"2019","journal-title":"Ann. Gastroenterol. Surg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.ejso.2007.01.007","article-title":"The Role of Staging Laparoscopy in Esophagogastric Cancers","volume":"33","author":"Ayantunde","year":"2007","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.semradonc.2012.09.002","article-title":"Surgical Management of Gastroesophageal Junction Tumors","volume":"23","author":"Amenabar","year":"2013","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"6608","DOI":"10.3748\/wjg.v12.i41.6608","article-title":"Surgical Management of Esophagogastric Junction Tumors","volume":"12","author":"Stein","year":"2006","journal-title":"World J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"8485","DOI":"10.1245\/s10434-021-10346-x","article-title":"Esophagectomy or Total Gastrectomy for Siewert 2 Gastroesophageal Junction (GEJ) Adenocarcinoma? A Registry-Based Analysis","volume":"28","author":"Kamarajah","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/nyas.14454","article-title":"Current Surgical Treatment Standards for Esophageal and Esophagogastric Junction Cancer","volume":"1482","author":"Jung","year":"2020","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"209","DOI":"10.5230\/jgc.2018.18.e28","article-title":"Surgical Treatment of Gastroesophageal Junction Cancer","volume":"18","author":"Hashimoto","year":"2018","journal-title":"J. Gastric Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.21037\/tgh.2019.09.13","article-title":"Significance of Nodal Dissection and Nodal Positivity in Gastric Cancer","volume":"5","author":"Zhang","year":"2020","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Dinescu, V.-C., Gheorman, V., Georgescu, E.F., Paitici, \u0218., Bic\u0103, M., P\u0103tra\u0219cu, \u0218., Bunescu, M.G., Popa, R., Berceanu, M.C., and P\u0103tra\u0219cu, A.M. (2023). Uncovering the Impact of Lymphadenectomy in Advanced Gastric Cancer: A Comprehensive Review. Life, 13.","DOI":"10.3390\/life13081769"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12957-024-03388-4","article-title":"Optimal Lymph Node Dissection for Gastric Cancer: A Narrative Review","volume":"22","author":"Nico","year":"2024","journal-title":"World J. Surg. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Cai, Z., Yin, Y., Zhao, Z., Xin, C., Cai, Z., Yin, Y., Shen, C., Yin, X., Wang, J., and Chen, Z. (2018). Comparative Effectiveness of Neoadjuvant Treatments for Resectable Gastroesophageal Cancer: A Network Meta-Analysis. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.00872"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1039-e642","DOI":"10.1634\/theoncologist.2019-0330","article-title":"Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric\/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up","volume":"24","author":"Rosenberg","year":"2019","journal-title":"Oncologist"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","article-title":"Perioperative Chemotherapy with Fluorouracil plus Leucovorin, Oxaliplatin, and Docetaxel versus Fluorouracil or Capecitabine plus Cisplatin and Epirubicin for Locally Advanced, Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma (FLOT4): A Randomised, Phase 2\/3 Trial","volume":"393","author":"Homann","year":"2019","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1056\/NEJMoa2503701","article-title":"Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer","volume":"393","author":"Janjigian","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer","volume":"366","author":"Hulshof","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_32","first-page":"30","article-title":"ESOPEC trial: Enhancing treatment approaches for esophageal adenocarcinoma","volume":"10","author":"Modi","year":"2024","journal-title":"J. Cancer Metastasis Treat."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/jgh3.12727","article-title":"Localized Stomach Cancer: Perioperative or Postoperative Approach? A Meta-analysis of Phase III Studies","volume":"6","author":"Rejab","year":"2022","journal-title":"JGH Open"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41571-019-0215-3","article-title":"Perioperative FLOT Superior to ECF\/X","volume":"16","author":"Bradley","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Lin, Y., Liang, H.-W., Liu, Y., and Pan, X.-B. (2023). Nivolumab Adjuvant Therapy for Esophageal Cancer: A Review Based on Subgroup Analysis of CheckMate 577 Trial. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1264912"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1200\/JCO.23.00975","article-title":"Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II\/III DANTE\/IKF-S633 Trial","volume":"42","author":"Lorenzen","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Smyth, E., Kn\u00f6dler, M., Giraut, A., Mauer, M., Nilsson, M., Van Grieken, N., Wagner, A.D., Moehler, M., and Lordick, F. (2019). VESTIGE: Adjuvant Immunotherapy in Patients with Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy with High Risk for Recurrence (N+ and\/or R1): An Open Label Randomized Controlled Phase-2-Study. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.01320"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/ijc.29403","article-title":"NeoFLOT: Multicenter Phase II Study of Perioperative Chemotherapy in Resectable Adenocarcinoma of the Gastroesophageal Junction or Gastric Adenocarcinoma-Very Good Response Predominantly in Patients with Intestinal Type Tumors","volume":"137","author":"Schulz","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.gie.2019.03.022","article-title":"A Survival Guide to HER2 Testing in Gastric\/Gastroesophageal Junction Carcinoma","volume":"90","author":"Subasinghe","year":"2019","journal-title":"Gastrointest. Endosc."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"771","DOI":"10.21037\/jgo.2016.08.06","article-title":"The Promise of PD-1 Inhibitors in Gastro-Esophageal Cancers: Microsatellite Instability vs. PD-L1","volume":"7","author":"Jin","year":"2016","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13045-019-0738-1","article-title":"Mismatch Repair Deficiency\/Microsatellite Instability-High as a Predictor for Anti-PD-1\/PD-L1 Immunotherapy Efficacy","volume":"12","author":"Zhao","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_43","first-page":"465","article-title":"Evidence in Follow-up and Prognosis of Esophagogastric Junction Cancer","volume":"97","year":"2019","journal-title":"Cir. Esp."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Giampieri, R., Baleani, M.G., Bittoni, A., Rastelli, F., Catalano, V., Del Prete, M., Chiorrini, S., Pinterpe, G., Graziano, F., and Giorgi, F.C. (2023). Impact of Signet-Ring Cell Histology in the Management of Patients with Non-Metastatic Gastric Cancer: Results from a Retrospective Multicenter Analysis Comparing FLOT Perioperative Chemotherapy vs. Surgery Followed by Adjuvant Chemotherapy. Cancers, 15.","DOI":"10.3390\/cancers15133342"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Du, H., Wang, N., Wang, L., and Huang, Y. (2024). An Update of Clinical Value of Circulating Tumor DNA in Esophageal Cancer: A Systematic Review and Meta-Analysis. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-11879-6"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.18632\/oncotarget.14064","article-title":"Diagnostic and Prognostic Value of Circulating Tumor DNA in Gastric Cancer: A Meta-Analysis","volume":"8","author":"Gao","year":"2016","journal-title":"Oncotarget"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e36228","DOI":"10.1097\/MD.0000000000036228","article-title":"Circulating Tumor DNA Predicts Recurrence and Assesses Prognosis in Operable Gastric Cancer: A Systematic Review and Meta-Analysis","volume":"102","author":"Mi","year":"2023","journal-title":"Medicine"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","article-title":"Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer","volume":"358","author":"Cunningham","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1200\/JCO.2007.13.9378","article-title":"Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie","volume":"26","author":"Hartmann","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_50","first-page":"12","article-title":"Quality of Life During Palliative Systemic Therapy for Esophagogastric Cancer: Systematic Review and Meta-Analysis","volume":"112","author":"Schokker","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1200\/JCO.2005.05.0245","article-title":"Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate Data","volume":"24","author":"Wagner","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","article-title":"Nivolumab plus Chemotherapy versus Placebo plus Chemotherapy in Patients with HER2-Negative, Untreated, Unresectable Advanced or Recurrent Gastric or Gastro-Oesophageal Junction Cancer (ATTRACTION-4): A Randomised, Multicentre, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus Chemotherapy versus Placebo plus Chemotherapy for HER2-Negative Advanced Gastric Cancer (KEYNOTE-859): A Multicentre, Randomised, Double-Blind, Phase 3 Trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e078876","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus Chemotherapy versus Placebo plus Chemotherapy as First Line Treatment for Advanced Gastric or Gastro-Oesophageal Junction Adenocarcinoma: RATIONALE-305 Randomised, Double Blind, Phase 3 Trial","volume":"385","author":"Qiu","year":"2024","journal-title":"BMJ"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1200\/JCO.2023.41.4_suppl.291","article-title":"Nivolumab (NIVO) plus Chemotherapy (Chemo) vs. Chemo as First-Line (1L) Treatment for Advanced Gastric Cancer\/Gastroesophageal Junction Cancer\/Esophageal Adenocarcinoma (GC\/GEJC\/EAC): 3-Year Follow-up from CheckMate 649","volume":"41","author":"Janjigian","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-Line Nivolumab plus Chemotherapy versus Chemotherapy Alone for Advanced Gastric, Gastro-Oesophageal Junction, and Oesophageal Adenocarcinoma (CheckMate 649): A Randomised, Open-Label, Phase 3 Trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1200\/JCO.2023.41.4_suppl.290","article-title":"Nivolumab (NIVO) plus Chemotherapy (Chemo) or Ipilimumab (IPI) vs Chemo as First-Line (1L) Treatment for Advanced Esophageal Squamous Cell Carcinoma (ESCC): 29-Month (Mo) Follow-up from CheckMate 648","volume":"41","author":"Kato","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus Chemotherapy versus Chemotherapy Alone for First-Line Treatment of Advanced Oesophageal Cancer (KEYNOTE-590): A Randomised, Placebo-Controlled, Phase 3 Study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.22.02331","article-title":"Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline","volume":"41","author":"Shah","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in Combination with Chemotherapy versus Chemotherapy Alone for Treatment of HER2-Positive Advanced Gastric or Gastro-Oesophageal Junction Cancer (ToGA): A Phase 3, Open-Label, Randomised Controlled Trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","article-title":"The KEYNOTE-811 Trial of Dual PD-1 and HER2 Blockade in HER2-Positive Gastric Cancer","volume":"600","author":"Janjigian","year":"2021","journal-title":"Nature"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/cam4.1372","article-title":"Microsatellite Instability Status Determined by Next-Generation Sequencing and Compared with PD-L1 and Tumor Mutational Burden in 11,348 Patients","volume":"7","author":"Vanderwalde","year":"2018","journal-title":"Cancer Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-Line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1200\/JCO.2022.40.4_suppl.243","article-title":"Pembrolizumab with or without Chemotherapy versus Chemotherapy Alone for Patients with PD-L1\u2013Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: Update from the Phase 3 KEYNOTE-062 Trial","volume":"40","author":"Wainberg","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.annonc.2023.01.006","article-title":"VP1-2023: Pembrolizumab (Pembro) plus Chemotherapy (Chemo) as First-Line Therapy for Advanced HER2-Negative Gastric or Gastroesophageal Junction (G\/GEJ) Cancer: Phase III KEYNOTE-859 Study","volume":"34","author":"Rha","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_67","unstructured":"(2025, April 25). Nivolumab Plus Chemotherapy vs. Chemotherapy as First-Line Treatment for Advanced Gastric Cancer\/Gastroesophageal Junction Cancer\/Esophageal Adenocarcinoma: 4-Year Follow-Up of the CheckMate 649 Study. Available online: https:\/\/www.onclive.com\/view\/nivolumab-plus-chemotherapy-vs-chemotherapy-as-first-line-treatment-for-advanced-gastric-cancer-gastroesophageal-junction-cancer-esophageal-adenocarcinoma-4-year-follow-up-of-checkmate-649."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"S1329","DOI":"10.1016\/j.annonc.2021.08.2131","article-title":"LBA7 Nivolumab (NIVO) plus Chemotherapy (Chemo) or Ipilimumab (IPI) vs Chemo as First-Line (1L) Treatment for Advanced Gastric Cancer\/Gastroesophageal Junction Cancer\/Esophageal Adenocarcinoma (GC\/GEJC\/EAC): CheckMate 649 Study","volume":"32","author":"Janjigian","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","article-title":"Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Ajani","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/cac2.12193","article-title":"The Chinese Society of Clinical Oncology (CSCO): Clinical Guidelines for the Diagnosis and Treatment of Gastric Cancer, 2021","volume":"41","author":"Wang","year":"2021","journal-title":"Cancer Commun."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e180013","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in Patients with Advanced Gastric or Gastro-Oesophageal Junction Cancer Refractory to, or Intolerant of, at Least Two Previous Chemotherapy Regimens (ONO-4538-12, ATTRACTION-2): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1093\/annonc\/mdy264","article-title":"Phase III, Randomised Trial of Avelumab versus Physician\u2019s Choice of Chemotherapy as Third-Line Treatment of Patients with Advanced Gastric or Gastro-Oesophageal Junction Cancer: Primary Analysis of JAVELIN Gastric 300","volume":"29","author":"Bang","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/S1470-2045(22)00603-9","article-title":"Bemarituzumab in Patients with FGFR2b-Selected Gastric or Gastro-Oesophageal Junction Adenocarcinoma (FIGHT): A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Study","volume":"23","author":"Wainberg","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"S306","DOI":"10.1016\/j.annonc.2022.04.249","article-title":"P-159 Trastuzumab Deruxtecan (T-DXd) in Patients with HER2-Positive Gastric Cancer (GC) or Gastroesophageal Junction (GEJ) Adenocarcinoma Who Have Progressed on or after a Trastuzumab-Containing Regimen (DESTINY-Gastric04): A Randomized Phase 3 Study","volume":"33","author":"Shitara","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1200\/JCO.20.01888","article-title":"Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer","volume":"38","author":"Kojima","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","article-title":"Nivolumab versus Chemotherapy in Patients with Advanced Oesophageal Squamous Cell Carcinoma Refractory or Intolerant to Previous Chemotherapy (ATTRACTION-3): A Multicentre, Randomised, Open-Label, Phase 3 Trial","volume":"20","author":"Kato","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus Paclitaxel versus Placebo plus Paclitaxel in Patients with Previously Treated Advanced Gastric or Gastro-Oesophageal Junction Adenocarcinoma (RAINBOW): A Double-Blind, Randomised Phase 3 Trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejca.2022.01.015","article-title":"FOLFIRI plus Ramucirumab versus Paclitaxel plus Ramucirumab as Second-Line Therapy for Patients with Advanced or Metastatic Gastroesophageal Adenocarcinoma with or without Prior Docetaxel-Results from the Phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO","volume":"165","author":"Lorenzen","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1470-2045(13)70549-7","article-title":"Docetaxel versus Active Symptom Control for Refractory Oesophagogastric Adenocarcinoma (COUGAR-02): An Open-Label, Phase 3 Randomised Controlled Trial","volume":"15","author":"Ford","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/jnci\/86.14.1086","article-title":"Activity of Taxol in Patients with Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus","volume":"86","author":"Ajani","year":"1994","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00280-012-2027-3","article-title":"A Randomized Phase II Study of Biweekly Irinotecan Monotherapy or a Combination of Irinotecan plus 5-Fluorouracil\/Leucovorin (mFOLFIRI) in Patients with Metastatic Gastric Adenocarcinoma Refractory to or Progressive after First-Line Chemotherapy","volume":"71","author":"Sym","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab Monotherapy for Previously Treated Advanced Gastric or Gastro-Oesophageal Junction Adenocarcinoma (REGARD): An International, Randomised, Multicentre, Placebo-Controlled, Phase 3 Trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","article-title":"Trifluridine\/Tipiracil versus Placebo in Patients with Heavily Pretreated Metastatic Gastric Cancer (TAGS): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"19","author":"Shitara","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1200\/JCO.2015.65.1901","article-title":"Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial","volume":"34","author":"Pavlakis","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"LBA294","DOI":"10.1200\/JCO.2023.41.4_suppl.LBA294","article-title":"INTEGRATE IIa: A Randomised, Double-Blind, Phase III Study of Regorafenib versus Placebo in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)\u2014A Study Led by the Australasian Gastro-Intestinal Trials Group (AGITG)","volume":"41","author":"Pavlakis","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","article-title":"Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients with Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction","volume":"34","author":"Li","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"v877","DOI":"10.1093\/annonc\/mdz394.034","article-title":"Randomized Phase III ANGEL Study of Rivoceranib (Apatinib) + Best Supportive Care (BSC) vs Placebo + BSC in Patients with Advanced\/Metastatic Gastric Cancer Who Failed \u22652 Prior Chemotherapy Regimens","volume":"30","author":"Kang","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/cac2.12379","article-title":"A Phase Ib\/II Study of Fruquintinib in Combination with Paclitaxel as the Second-line Therapy for Advanced Gastric Cancer","volume":"43","author":"Zhang","year":"2022","journal-title":"Cancer Commun."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1038\/s41591-024-02989-6","article-title":"Fruquintinib plus Paclitaxel versus Placebo plus Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma: The Randomized Phase 3 FRUTIGA Trial","volume":"30","author":"Wang","year":"2024","journal-title":"Nat. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"LBA292","DOI":"10.1200\/JCO.2023.41.4_suppl.LBA292","article-title":"Zolbetuximab + mFOLFOX6 as First-Line (1L) Treatment for Patients (Pts) Withclaudin-18.2+ (CLDN18.2+) \/ HER2\u2212 Locally Advanced (LA) Unresectable or Metastatic Gastric or Gastroesophageal Junction (mG\/GEJ) Adenocarcinoma: Primary Results from Phase 3 SPOTLIGHT Study","volume":"41","author":"Shitara","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_94","unstructured":"Food and Drug Administration, and Research Center for Drug Evaluation (2024). FDA Approves Zolbetuximab-Clzb with Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma, FDA."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma: The Randomized, Phase 3 GLOW Trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat. Med."},{"key":"ref_96","unstructured":"News|Astellas Pharma Inc. (2025, April 25). Available online: https:\/\/www.astellas.com\/content\/dam\/astellas-com\/global\/en\/documents\/vyloy_pi.pdf."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"S1044","DOI":"10.1016\/j.annonc.2021.08.1489","article-title":"1380P Phase (Ph) II Study of Zanidatamab + Chemotherapy (Chemo) in First-Line (1L) HER2 Expressing Gastroesophageal Adenocarcinoma (GEA)","volume":"32","author":"Ku","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_98","unstructured":"(2025, April 25). Diana Zymeworks Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024. Available online: https:\/\/www.zymeworks.com\/zymeworks-presents-updated-phase-2-data-for-zanidatamab-demonstrating-increased-mpfs-in-her2-positive-metastatic-gastroesophageal-adenocarcinoma-at-esmo-2024\/."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.2217\/fon-2021-0176","article-title":"KEYNOTE-859: A Phase III Study of Pembrolizumab plus Chemotherapy in Gastric\/Gastroesophageal Junction Adenocarcinoma","volume":"17","author":"Tabernero","year":"2021","journal-title":"Future Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.2217\/fon-2022-1148","article-title":"LEAP-014: First-Line Lenvatinib + Pembrolizumab + Chemotherapy in Advanced\/Metastatic Esophageal Squamous Cell Carcinoma","volume":"20","author":"Sun","year":"2024","journal-title":"Future Oncol."},{"key":"ref_101","unstructured":"Reuters (2025, April 25). Merck, Eisai\u2019s Combination Drug Fails in Late-Stage Trial for Esophageal Cancer. Available online: https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/merck-eisais-cancer-drugs-fail-improve-overall-survival-late-stage-trial-2025-01-24\/."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1200\/JCO.22.00686","article-title":"Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair\/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study","volume":"41","author":"Tougeron","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_103","unstructured":"Vu, Q.D., Fong, C., Gordon, A., Lund, T., Silveira, T.L., Rodrigues, D., von Loga, K., Raza, S.E.A., Cunningham, D., and Rajpoot, N. (2024). An AI Based Digital Score of Tumour-Immune Microenvironment Predicts Benefit to Maintenance Immunotherapy in Advanced Oesophagogastric Adenocarcinoma. arXiv."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1200\/JCO.19.03296","article-title":"Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)","volume":"38","author":"Fukuoka","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S1470-2045(20)30271-0","article-title":"Lenvatinib plus Pembrolizumab in Patients with Advanced Gastric Cancer in the First-Line or Second-Line Setting (EPOC1706): An Open-Label, Single-Arm, Phase 2 Trial","volume":"21","author":"Kawazoe","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_106","unstructured":"(2025, April 25). INTEGRATE IIb. Available online: https:\/\/gicancer.org.au\/clinical-trial\/integrate-iib\/."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Peshin, S., Bashir, F., Kodali, N.A., Dharia, A., Zaiter, S., Singal, S., and Moka, N. (2025). Immunotherapy in GI Cancers: Lessons from Key Trials and Future Clinical Applications. Antibodies, 14.","DOI":"10.3390\/antib14030058"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S1470-2045(17)30111-0","article-title":"Trastuzumab Emtansine versus Taxane Use for Previously Treated HER2-Positive Locally Advanced or Metastatic Gastric or Gastro-Oesophageal Junction Adenocarcinoma (GATSBY): An International Randomised, Open-Label, Adaptive, Phase 2\/3 Study","volume":"18","author":"Shah","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1200\/JCO.2015.62.6598","article-title":"Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013\/LOGiC\u2014A Randomized Phase III Trial","volume":"34","author":"Hecht","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2013.53.6136","article-title":"Lapatinib plus Paclitaxel versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN\u2014A Randomized, Phase III Study","volume":"32","author":"Satoh","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S1470-2045(13)70102-5","article-title":"Capecitabine and Cisplatin with or without Cetuximab for Patients with Previously Untreated Advanced Gastric Cancer (EXPAND): A Randomised, Open-Label Phase 3 Trial","volume":"14","author":"Lordick","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1470-2045(13)70096-2","article-title":"Epirubicin, Oxaliplatin, and Capecitabine with or without Panitumumab for Patients with Previously Untreated Advanced Oesophagogastric Cancer (REAL3): A Randomised, Open-Label Phase 3 Trial","volume":"14","author":"Waddell","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1200\/JCO.2011.36.2236","article-title":"Bevacizumab in Combination with Chemotherapy as First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study","volume":"29","author":"Ohtsu","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jamaoncol.2016.5580","article-title":"Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial","volume":"3","author":"Shah","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S1470-2045(17)30566-1","article-title":"Rilotumumab plus Epirubicin, Cisplatin, and Capecitabine as First-Line Therapy in Advanced MET-Positive Gastric or Gastro-Oesophageal Junction Cancer (RILOMET-1): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"18","author":"Catenacci","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1200\/JCO.2012.48.3552","article-title":"Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study","volume":"31","author":"Ohtsu","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S1470-2045(17)30682-4","article-title":"Olaparib in Combination with Paclitaxel in Patients with Advanced Gastric Cancer Who Have Progressed Following First-Line Therapy (GOLD): A Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial","volume":"18","author":"Bang","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1200\/JCO-24-01619","article-title":"Targeting DKK1 to Remodel the Tumor Microenvironment and Enhance Immune Checkpoint Blockade Therapy","volume":"43","author":"Shi","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Zhang, J., Tang, P.M.K., Zhou, Y., Cheng, A.S.L., Yu, J., Kang, W., and To, K.F. (2019). Targeting the Oncogenic FGF-FGFR Axis in Gastric Carcinogenesis. Cells, 8.","DOI":"10.3390\/cells8060637"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41571-018-0115-y","article-title":"Fibroblast Growth Factor Receptors as Treatment Targets in Clinical Oncology","volume":"16","author":"Katoh","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_121","first-page":"e677","article-title":"Immune Consequences of Tyrosine Kinase Inhibitors That Synergize with Cancer Immunotherapy","volume":"2","author":"Kwilas","year":"2015","journal-title":"Cancer Cell Microenviron."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.annonc.2021.02.005","article-title":"FAST: A Randomised Phase II Study of Zolbetuximab (IMAB362) plus EOX versus EOX Alone for First-Line Treatment of Advanced CLDN18.2-Positive Gastric and Gastro-Oesophageal Adenocarcinoma","volume":"32","author":"Sahin","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_123","unstructured":"News|Astellas Pharma Inc. (2025, May 29). Available online: https:\/\/newsroom.astellas.com\/2025-10-13-Astellas-Confirms-Phase-2-GLEAM-Trial-Did-Not-Meet-Primary-Endpoint-of-Overall-Survival-in-Patients-with-Metastatic-Pancreatic-Cancer."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1981202","DOI":"10.1080\/19420862.2021.1981202","article-title":"Preclinical Characterization of Bemarituzumab, an Anti-FGFR2b Antibody for the Treatment of Cancer","volume":"13","author":"Xiang","year":"2021","journal-title":"MAbs"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1146\/annurev.cellbio.20.010403.113126","article-title":"The Wnt Signaling Pathway in Development and Disease","volume":"20","author":"Logan","year":"2004","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.devcel.2009.06.016","article-title":"Wnt\/Beta-Catenin Signaling: Components, Mechanisms, and Diseases","volume":"17","author":"MacDonald","year":"2009","journal-title":"Dev. Cell"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/nrd2154","article-title":"Mining the Wnt Pathway for Cancer Therapeutics","volume":"5","author":"Barker","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"e1093","DOI":"10.1038\/cddis.2014.67","article-title":"An Unexpected Role for a Wnt-Inhibitor: Dickkopf-1 Triggers a Novel Cancer Survival Mechanism through Modulation of Aldehyde-Dehydrogenase-1 Activity","volume":"5","author":"Krause","year":"2014","journal-title":"Cell Death Dis."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1161\/ATVBAHA.110.213751","article-title":"The Wnt Antagonist Dickkopf-1 Increases Endothelial Progenitor Cell Angiogenic Potential","volume":"30","author":"Smadja","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.cell.2016.02.025","article-title":"Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT","volume":"165","author":"Malladi","year":"2016","journal-title":"Cell"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1200\/JCO.2022.40.4_suppl.292","article-title":"DKN-01 and Tislelizumab \u00b1 Chemotherapy as a First-Line (1L) and Second-Line (2L) Investigational Therapy in Advanced Gastroesophageal Adenocarcinoma (GEA): DisTinGuish Trial","volume":"40","author":"Klempner","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1200\/JCO.24.00410","article-title":"DKN-01 and Tislelizumab + Chemotherapy as First-Line (1L) Investigational Therapy in Advanced Gastroesophageal Adenocarcinoma (GEA): DisTinGuish Trial","volume":"43","author":"Klempner","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Nishida, N. (2021). Role of Oncogenic Pathways on the Cancer Immunosuppressive Microenvironment and Its Clinical Implications in Hepatocellular Carcinoma. Cancers, 13.","DOI":"10.3390\/cancers13153666"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Kato, Y., Tabata, K., Kimura, T., Yachie-Kinoshita, A., Ozawa, Y., Yamada, K., Ito, J., Tachino, S., Hori, Y., and Matsuki, M. (2019). Lenvatinib plus Anti-PD-1 Antibody Combination Treatment Activates CD8+ T Cells through Reduction of Tumor-Associated Macrophage and Activation of the Interferon Pathway. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0212513"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Li, W., Huang, Y., Zhou, X., Cheng, B., Wang, H., and Wang, Y. (2024). CAR-T therapy for gastrointestinal cancers: Current status, challenges, and future directions. Braz. J. Med. Biol. Res., 57.","DOI":"10.1590\/1414-431x2024e13640"},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Peshin, S., Takrori, E., Kodali, N.A., Bashir, F., and Singal, S. (2025). Advances in the Management of Pancreatic Cancer: Current Strategies and Emerging Therapies. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26157055"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"38","DOI":"10.21037\/jgo-21-50","article-title":"CD276 suppresses CAR-T cell function by promoting tumor cell glycolysis in esophageal squamous cell carcinoma","volume":"12","author":"Yue","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"101138","DOI":"10.1016\/j.tranon.2021.101138","article-title":"Targeting CD276 by CAR-T cells induces regression of esophagus squamous cell carcinoma in xenograft mouse models","volume":"14","author":"Xuan","year":"2021","journal-title":"Transl. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Feng, Q., Sun, B., Xue, T., Li, R., Lin, C., Gao, Y., Sun, L., Zhuo, Y., and Wang, D. (2022). Advances in CAR T-cell therapy in bile duct, pancreatic, and gastric cancers. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1025608"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(25)00860-8","article-title":"Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician\u2019s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): A randomised, open-label, phase 2 trial","volume":"405","author":"Qi","year":"2025","journal-title":"Lancet"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e202500351","DOI":"10.1002\/smsc.202500351","article-title":"Nanoscale Analysis beyond Imaging by Atomic Force Microscopy: Molecular Perspectives on Oncology and Neurodegeneration","volume":"5","author":"Marcuello","year":"2025","journal-title":"Small Sci."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1422185","DOI":"10.1155\/2022\/1422185","article-title":"Nanoscale Features of Gambogic Acid Induced ROS-Dependent Apoptosis in Esophageal Cancer Cells Imaged by Atomic Force Microscopy","volume":"2022","author":"Liu","year":"2022","journal-title":"Scanning"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/23\/11424\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T11:44:28Z","timestamp":1764157468000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/23\/11424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":142,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["ijms262311424"],"URL":"https:\/\/doi.org\/10.3390\/ijms262311424","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]}}}